



Karen Luong

PARTNER

THE LINK VIRTUAL OFFICE

PHONE: 213.337.6559

EMAIL: KAREN.LUONG@HUSCHBLACKWELL.COM

LOS ANGELES, CA*

PHONE: 213.337.6550

OVERVIEW

Karen guides clients through high-stakes litigation, focusing on product liability and mass tort matters.

Manufacturers, construction companies, automotive manufacturers and retailers, insurers, contractors, suppliers and business owners are a few of the clients relying on Karen's experience, counsel and defense. She is well versed in complex litigation involving toxic products, materials and chemicals. Karen regularly represents clients in state and federal court in matters of product liability, premises liability, personal injury and other complex allegations. She is known for her ability to defend client reputation along with the legal claims at hand.

Karen is the co-founder and co-lead of the firm's Psychedelic and Emerging Therapies practice group. This groundbreaking group guides researchers, manufacturers, investors, clinicians and other participants around and through the myriad obstacles that result from the patchwork of state and federal laws regulating Schedule I controlled substances.

In addition to Karen's focus on psychedelic law and complex products liability, she also has experience representing clients in general commercial litigation, business litigation and the cannabis industry.

Industries

Manufacturing
Technology
Transportation

Services

Cannabis
Product Liability
Toxic Tort
Asbestos Litigation
Psychedelics & Emerging Therapies

"Karen has a noteworthy depth of knowledge."

— Chambers USA 2025

Experience

- Obtained complete dismissal on behalf of talc supplier in jury trial arising from allegations that its talc, later incorporated into baby powder, was contaminated.
- Defended construction materials company against claims of injury from alleged exposure to asbestos-containing products during plaintiff's work on various construction sites. Secured favorable outcome for client.
- Defended equipment manufacturer in injury and wrongful death allegations brought by familial survivors, claiming exposure to asbestos during decedent's work aboard Navy vessels. Secured favorable outcome for client.
- Advised higher education client on federal regulations and California law governing who is able to prescribe, administer and dispense controlled substances under California law, information needed for DEA licensing requirements, and clinic licensing requirements for human studies involving psychedelic substances.
- Advised business on current state and federal drug paraphernalia laws and liability issues related to psychedelic substances.

Recognition

- *Chambers USA*, Psychedelics Law, Nationwide, 2025
- *National Law Journal's* Emerging Therapies/Life Sciences Trailblazers
- Top 200 Global Psychedelic Lawyers and Policy & Regulatory Experts, 2023-2025
- National Asian Pacific American Bar Association (NAPABA) Prospective Partners Program, 2022
- Southern California Super Lawyers, Rising Star, 2015-2020

Education

- J.D., University of San Diego School of Law
- B.A., University of California, Irvine
 - English, International Studies

Admissions

- California
- U.S. Court of Appeals, Ninth Circuit
- U.S. District Court, Central District of California
- U.S. District Court, Eastern District of California
- U.S. District Court, Northern District of California
- U.S. District Court, Southern District of California

Community Leadership

Karen represented a large cohort of physicians and clinicians in their amicus brief in AIMS vs. DEA, a landmark case in the 9th Circuit Court of Appeals that involves a direct petition to the DEA to reschedule psilocybin from schedule 1 to schedule 2 of the Controlled Substances Act.

Karen also serves her community through leadership roles in multiple non-profit organizations. She is a member of the Board of Governors for Womens Law Association of Los Angeles and American Business Trial Lawyers Los Angeles.

*Contact Karen to set up an in-person consultation by appointment in the Los Angeles office.



Chambers USA 2025.